

ORIGINAL ARTICLE

Age, sex and the association between skin test responses and IgE titres with asthma

Hasan Raza Mohammad¹, Danielle Belgrave², Kamilla Kopec Harding¹, Clare S. Murray¹, Angela Simpson^{1,*} & Adnan Custovic^{2,*}

¹Centre for Respiratory Medicine and Allergy, Institute of Inflammation and Repair, Manchester Academic Health Science Centre, University of Manchester & University Hospital of South Manchester, Manchester, UK; ²Department of Paediatrics, Imperial College London, London, UK

To cite this article: Mohammad HR, Belgrave D, Kopec Harding K, Murray CS, Simpson A, Custovic A. Age, sex and the association between skin test responses and IgE titres with asthma. *Pediatr Allergy Immunol* 2016; **00**.

Keywords

childhood asthma; wheeze; age; sex; quantitative atopy; sIgE; skin tests

Correspondence

Hasan Raza Mohammad, UHSM, Manchester, M23 9LT, UK
Tel.: 07841873244
Fax: 01612915781
E-mail: hasanmohammad@doctors.org.uk

*Joint senior authors.

Accepted for publication 9 January 2016

DOI:10.1111/pai.12534

Abstract

Background: Skin prick tests (SPTs) and allergen-specific serum IgE (sIgE) measurements are the main diagnostic tools for confirming atopic sensitization. Results are usually reported as 'positive' or 'negative', using the same arbitrary cut-offs (SPT >3 mm, sIgE >0.35 kU_A/l) across different ages and sexes. We investigated the influence of age and sex on the interpretation of allergy test in the context of childhood asthma.

Methods: In a population-based birth cohort (n = 1051), we ascertained the information on asthma/wheeze (validated questionnaires) and performed SPTs and sIgE measurement to inhalant allergens (dust mite, cat, dog) at follow-ups between ages three and 11 years. We investigated the association between quantitative sensitization (sum of SPT mean wheal diameters [MWD] and sIgE titres to the three allergens) and current wheeze and asthma across ages and sexes.

Results: We observed a significant association between the SPT MWD and sIgE titres and wheeze/asthma at most ages and for both sexes. However, the strength of this association was age- and sex-dependent. For SPTs, the strength of the association between MWD and asthma increased with increasing age; we observed the opposite pattern for sIgE titre. For any given SPT MWD/sIgE titre, boys were significantly more likely to express clinical symptoms, particularly in early life; this difference between males and females diminished with age and was no longer significant by age 11 years.

Conclusions: Age and sex should be taken into account when interpreting the results of skin tests and sIgE measurement, and age- and sex-specific normative data are needed for these allergy tests.

Atopic sensitization has been identified as a risk factor for asthma in a series of epidemiological studies (1–4). Skin prick tests (SPTs) and measurements of serum allergen-specific IgE antibodies (sIgE) are the most commonly used diagnostic tools for confirming sensitization. Both of these allergy tests are usually reported as either positive or negative (1–4), with SPT mean wheal diameter (MWD) at least 3 mm greater than the negative control and sIgE titre >0.35 kU_A/l generally considered as indices of sensitization (5). However, these cut-offs are arbitrary, and different decision points are sometimes utilized.

In relation to the presence or absence of allergic disease, using the results of SPTs and sIgE measurement as

dichotomous outcomes has high negative predictive values, but relatively poorer positive predictive values (5, 6), and individuals classified as 'sensitized' often do not express any symptoms of allergic disease (7). There is compelling evidence in food allergy that quantification of sensitization to food allergens (either as the size of skin test MWD or sIgE titre) predicts allergic reactions with much greater certainty than dichotomous cut-offs (8, 9). Similarly, we have previously shown in the context of respiratory allergy that the increasing titre of sIgEs to common inhalant allergens (mite, cat and dog) is strongly associated with childhood wheezing and diminished lung function (10), with a similar association between sIgE titre

to grass pollen and symptoms of rhinitis (11). Furthermore, the sum of sIgE titres to mite, cat and dog amongst wheezy children aged 3 years strongly predicted the risk of wheeze persistence into later childhood (10). Quantification of atopic sensitization may also have a role in ascertaining asthma control, with emerging evidence that asthma severity and the risk of future exacerbations increase with increasing size of skin tests and sIgE titres (12).

Total and specific IgE levels have been shown to change with age, sex, location/exposure and ethnicity (13–15). Total IgE tends to increase in childhood until the age of 9–10 years, after which the levels generally plateau (16). There is also evidence that males have higher total IgE compared to females (17). Similarly, the size of skin test reaction to both allergens and histamine changes with age (18, 19). Despite this evidence, current interpretation of these commonly used allergy tests in the context of respiratory allergy does not generally take into account either age or sex of the patient (20).

We hypothesized that the relationship between atopic sensitization and asthma differs between boys and girls, and at different ages. To address our hypothesis, we investigated the effects of age and sex on the association between sensitization as a quantitative trait (size of skin test wheal diameter and titre of sIgE) and childhood wheezing and asthma.

Methods

Study population

The Manchester Asthma and Allergy Study is a population-based birth cohort (21, 22). Subjects were recruited prenatally and followed prospectively. Local Research Ethics Committee approved the study; parents gave written informed consent.

Data sources

Children attended review clinics at ages three, five, eight and 11 years. Validated questionnaires were interviewer-administered to collect information on parentally reported symptoms and treatments received. We assessed sensitization to *Dermatophagoides pteronyssinus*, cat and dog using skin prick tests at all ages (Bayer, Elkhart, IN, USA); we measured sIgE to these inhalant allergens at ages three, five and 8 years (ImmunoCAP™, Phadia, Uppsala, Sweden).

Definition of variables

Quantitative atopic sensitization

SPT MWD for each individual allergen was determined by summing the largest wheal diameter and its perpendicular axis, then dividing by two. We used the sum of SPT MWDs to dust mite, cat and dog, and the sum of sIgE titres to these three allergens as markers of quantitative sensitization. The choice of allergens was based on our previous data that such definition of quantitative sensitization rendered the strongest association between aeroallergen sensitization with wheeze presence and persistence in our study population (10, 11).

To take into account the increase in histamine reactivity that occurs through life (19), we also expressed SPT results as a ratio of MWD to allergens/MWD to histamine control (10 mg/ml) at each age.

Current wheeze

Defined as a positive response to the question ‘Has your child had wheezing or whistling in the chest in the last 12 months?’

Current asthma

Defined as the presence of any two of the following three features: (i) Current wheeze; (ii) Current use of asthma medication; and (iii) Physician-diagnosed asthma ever (23).

Statistical analysis

Logistic regression was used to investigate whether quantitative atopy (separate models using SPT MWD and sIgE as covariates) is associated with wheeze/asthma at each age. Estimates of the magnitude of the effect were quantified as odds ratios (ORs) with 95% confidence intervals (95% CI). We then investigated whether the association between quantitative atopic sensitization and current wheeze/asthma was modified by sex by including a covariate for sex-by-sensitization interaction for each age group. Predicted probability curves were constructed using results obtained from logistic regression.

Analysis was then extended to a discrete-time longitudinal model to investigate whether the magnitude of quantitative sensitization is significantly associated with current wheeze/asthma. We investigated: (i) a main effects model where we assumed that the effect of quantitative sensitization on current wheeze/asthma was independent of age; and (ii) whether the effect of quantitative sensitization on current wheeze/asthma was significantly modified by age by including an interaction term for quantitative sensitization and age in model (i).

As asthma, eczema and rhinitis may coexist in the same individual children more commonly than expected by chance (24, 25), we carried out additional analyses to assess the above associations with asthma presenting with coexisting eczema and rhinitis.

Results

Participant flow and demographics

Participant flow is shown in Figure E1. Of the 1184 recruited participants, 133 were randomized to a primary prevention study and were excluded from this analysis. Of the 1051 eligible subjects (586 males), 864 underwent SPTs at age 3 years (of those, 23.5% had current wheeze, 14.7% had asthma, 9% were sensitized), 858 at age five (23.1% wheeze, 22.8% asthma, 12.9% sensitized), 836 at age eight (18.3% wheeze, 17.9% asthma, 15% sensitized) and 715 at age 11 years (20.8% wheeze, 20.7% asthma, 11.2% sensitized). Blood sample for sIgE measurements was provided by 178 children at age 3 years (21.9% wheeze, 9.6% asthma, 21.9% sensitized), 534 at age five (22.7% wheeze, 20.5% asthma, 22.5% sensitized) and 511 at age eight (18.4% wheeze, 16.0% asthma, 30.3%

sensitized). There were no significant differences in the outcomes and demographic characteristics between children included and excluded from the analyses (data available on request).

The cross-sectional association between skin test MWDs and sIgE titres to each individual allergen (mite, cat and dog) at different ages and the probability of contemporaneous current wheeze in the whole population is shown in Table E1; the results amongst males and females separately are presented in Table E2.




Figure 1 Fitted probability curves from longitudinal analysis of the effect of age on the relation between quantitative atopy and current wheeze. (a) SPT MWD (b) sIgE titre.

Quantitative sensitization and the risk of wheeze and asthma:

The impact of age

Current wheeze

Statistically significant differences in the relation between SPT MWD and current wheeze were found at different ages (Fig. 1a), with the strength of the association increasing with increasing age. The relative odds ratios from discrete longitudinal analysis comparing the association between SPT MWD and sIgE titre and wheeze between different ages are shown in Table 1. There were significant differences in the strength of the association of SPT MWD and wheeze between ages three and eight and 11 years, and ages five and 8 years, but not between ages three and five, and eight and 11 years (Fig. 1a, Table 1). However, no significant differences were observed between age groups for the association between sIgE titre and current wheeze (Fig. 1b).

Current asthma

Similar to the findings for current wheeze, the strength of the association between SPT MWD and asthma increased with increasing age, with significant differences in the slope between different ages (Fig. 2a, Table 2). Statistically significant differences in the strength of the association were also observed between sIgE titres and asthma at different age groups, but in contrast to the association for SPT MWDs, the strength of the association between sIgE and asthma decreased with increasing age (Table 2, Fig. 2b).

Quantitative sensitization and the risk of wheeze and asthma:

The impact of sex

There was a significant association ($p < 0.01$) between wheeze and asthma and the sum of SPT MWDs in both sexes and for all age groups (Table E3). The relation was also significant between the sIgE titres and both outcomes, except at age 3 years amongst girls ($p = 0.14$). Fig. 3 shows predicted probability curves illustrating the relation between quantitative

Table 1 The relative odds ratios from discrete longitudinal analysis comparing the association between SPT MWD and sIgEs and current wheeze

Age group comparisons	Relative odds ratios	Lower confidence interval (LCL)	Upper confidence interval (UCL)	p-value
SPT MWD (mite+cat+dog)				
3 and 5	1.03	0.96	1.11	0.43
3 and 8	1.22	1.12	1.33	<0.001
3 and 11	1.14	1.05	1.24	0.002
5 and 8	1.21	1.12	1.30	<0.001
8 and 11	1.05	0.98	1.13	0.14
sIgE titre (mite+cat+dog)				
3 and 5	0.96	0.92	1.00	0.056
3 and 8	0.97	0.93	1.01	0.18
5 and 8	0.99	0.97	1.01	0.23

Bold: significant changes in association.

atopic sensitization and current asthma amongst males and females (the associations for wheeze were almost identical; Table E3). For a given SPT MWD, males were significantly more likely to have wheeze/asthma than females at ages three and 5 years (Fig. 3a–b). This sex difference diminished with age and was no longer significant by age 8 years (Fig. 3c). Similarly, for a given sIgE titre, males were more likely to have clinical symptoms (Fig. 3). However, this was statistically significant only at age five for wheeze ($p = 0.03$).

An interactive logistic regression test revealed no significant interaction between sex and SPT MWD in relation to current

wheeze/asthma in all age groups, except at the age 11 years ($p = 0.04$), and no significant interaction between sex and sIgE titre.

Analysis of the effect of age and sex on the association between quantitative sensitization and asthma with coexisting eczema and rhinitis rendered similar results (Tables E4–5). Expressing SPT results as a ratio of MWD to allergens/MWD to histamine did not materially alter the results for any of the outcomes (Table E6–7).

Discussion

Key findings

In a population-based birth cohort, we observed a significant association between the SPT MWD and sIgE titres to common inhalant allergens and wheeze/asthma at different ages, and for both sexes. However, the strength of this association was both age- and sex-dependent. For SPTs, the strength of the association between MWD and asthma increased with increasing age; we observed opposite pattern for sIgE titre. For any given SPT MWD or sIgE titre, boys were significantly more likely to express clinical symptoms, particularly in early life; this difference between males and females appeared to diminish with age.

Limitations

As is the case with most epidemiological studies, we relied on parental reporting of symptoms to define current wheezing and asthma, and we acknowledge that this may lead to overestimation of their true prevalence. Although the definition of current asthma which we used is more stringent than a simple report of wheezing or a physician-diagnosed asthma only, it is reliant on parental reporting.

Although the follow-up rate of participant in the cohort was high, we were unable to obtain data on all outcomes (including answers to all questions, skin tests and sIgE) for all children.




Figure 2 Fitted probability curves from longitudinal analysis of the effect of age on the relation between quantitative atopy and current asthma. (a) SPT MWD (b) sIgE titre.

Table 2 The relative odds ratios from discrete longitudinal analysis for the association between quantitative sensitization and asthma at different ages

Age group comparisons	Relative odds ratios	Lower confidence interval (LCL)	Upper confidence interval (UCL)	p-value
SPT MWD (mite+cat+dog)				
3 and 5	1.04	0.96	1.12	0.34
3 and 8	1.20	1.10	1.30	<0.001
3 and 11	1.14	1.05	1.24	0.002
5 and 8	1.17	1.09	1.26	<0.001
8 and 11	1.06	0.99	1.13	0.10
sIgE titre (mite+cat+dog)				
3 and 5	0.97	0.94	0.99	0.029
3 and 8	0.97	0.94	0.99	0.029
5 and 8	0.98	0.97	0.99	0.04

Bold: Significant changes in association.




Figure 3 Predicted probability curves illustrating the relation between quantitative atopy and current asthma amongst males and females. (a–c) SPT MWD (d–f) sIgE titre.

This was particularly relevant for the assessment of sIgE at age 3 years, which was measured in a relatively small proportion of children whose parents agreed to venepuncture. It is likely that as a consequence of having lower number of study participants who provided blood sample for sIgE measurement at this age, we observed a significant association between sIgE titres and wheezing at all ages, with the exception of 3-year-old girls. However, it is of note that in the analyses which we carried out, there was no difference between children included or excluded in demographic characteristics and primary outcome measures, suggesting that it is unlikely that this has influenced the main results.

We have not measured sIgE at age 11 years; however, we present the sIgE data at three different ages (three, five and 8 years), which allowed us to carry out longitudinal analyses.

Our definition of quantitative sensitization included SPT and sIgE responses to mite, cat and dog, which were then related to lower respiratory tract symptoms. We wish to emphasize that different allergens may be relevant in other geographical regions, and for different clinical outcomes.

One strength of the study is a relatively large sample of children from the population-based birth cohort, suggesting that our results are broadly applicable to the general population.

We acknowledge that recent developments in molecular or component-resolved diagnostics may facilitate better assessment of allergic diseases compared to skin prick or sIgE tests to extracts made from whole allergen sources (26–28). However, it is likely that standard SPTs and sIgE measurements are going to be widely used in large parts of the world for years to come.

Meaning of the study

There was a striking difference in the age-related association between SPT MWDs and sIgE titres with wheezing and asthma. For SPT MWDs, we found that the strength of the association with clinical symptoms increased as the age increased. However, the opposite pattern was observed for sIgE titres, with the strength of the association with disease decreasing with increasing age. This may be due to differences between the two tests, with SPTs assessing the sIgE bound to mast cells in skin, and serum sIgE detecting free sIgE. One possible reason for the decrease in the strength of the association between sIgE and clinical symptoms in the older age groups could be due to the changes in the total IgE. The ratio of sIgE to total IgE may be a better biomarker in relation

to the symptoms of allergic disease compared to sIgE titre *per se*. If the total IgE titres increase at a faster rate than sIgE, this could decrease the ratio of total IgE/sIgE and hence reduce the probability of symptoms at a given sIgE level. It has recently been reported that amongst sensitized children, allergen-specific IgG antibodies and sIgG/sIgE ratios may be associated with the size of skin test responses and the probability of clinical symptoms (29). Little is known about temporal changes in inhalant allergen-specific IgG antibodies, or IgG/IgE ratios during childhood. One important message offered by our results is that sIgE and SPT should not be used interchangeably to determine atopic sensitization and that these two tests provide complementary, rather than identical information.

Our results suggest that for a given value of SPT MWD and sIgE titre, boys are more likely than girls to exhibit wheezing and asthma at all ages (although the magnitude of this differences appeared to diminish with age). It is well known that sex influences asthma development in a time-dependent fashion, with higher prevalence and more severe symptoms in boys than girls. However, this pattern reverses during adolescence, with females having a greater incidence and severity of symptoms as they reach adulthood (30). Most published reports speculate that this is due to a numerous changes occurring during puberty, although no precise mechanistic explanation for this time-dependent switch has been established.

In summary, our results suggest that in clinical practice both age and sex need to be taken into account when interpreting the results of allergy tests (skin tests and specific IgE measurement). We suggest that age- and sex-specific normative data for both skin tests and sIgE are needed to fully capitalize on the potential value of these tests in the context of lower respiratory symptoms during childhood.

Acknowledgments

We thank the children and parents of the Manchester Asthma and Allergy Study cohort for their commitment to the project and their continued support and enthusiasm. We acknowledge the dedication of the Manchester Asthma and Allergy Study research team (research fellows, nurses, physiologists, technicians and clerical staff).

Declaration of sources of funding

MRC Grants G0601361 and MR/K002449/1, and Asthma UK Grant No 04/014.

References

1. Sears M, Herbison G, Holdaway M, Hewitt C, Flannery EM, Silva P. The relative risks of sensitivity to grass pollen, house dust mite and cat dander in the development of childhood asthma. *Clin Exp Allergy* 1989; **19**: 419–24.
2. Gergen PJ, Turkeltaub PC. The association of individual allergen reactivity with respiratory disease in a national sample: data from the second National Health and Nutrition Examination Survey, 1976–1980 (NHANES II). *J Allergy Clin Immunol* 1992; **90**: 579–88.
3. Addo-Yobo EO, Custovic A, Taggart SC, Craven M, Bonnie B, Woodcock A. Risk factors for asthma in urban Ghana. *J Allergy Clin Immunol* 2001; **108**: 363–8.
4. Al-Mousawi MSH, Lovel H, Behbehani N, Arifhodzic N, Woodcock A, Custovic A. Asthma and sensitization in a community with low indoor allergen levels and low pet-keeping frequency. *J Allergy Clin Immunol* 2004; **114**: 1389–94.
5. Custovic A, Lazic N, Simpson A. Pediatric asthma and development of atopy. *Curr Opin Allergy Clin Immunol* 2013; **13**: 173–80.
6. Sampson HA. Update on food allergy. *J Allergy Clin Immunol* 2004; **113**: 805–19.
7. Sicherer SH, Wood RA, Abramson S, et al. Allergy testing in childhood: using

- allergen-specific IgE tests. *Pediatrics* 2012; **129**: 193–7.
8. Maloney JM, Rudengren M, Ahlstedt S, Bock SA, Sampson HA. The use of serum-specific IgE measurements for the diagnosis of peanut, tree nut, and seed allergy. *J Allergy Clin Immunol* 2008; **122**: 145–51.
9. Roberts G, Lack G. Diagnosing peanut allergy with skin prick and specific IgE testing. *J Allergy Clin Immunol* 2005; **115**: 1291–6.
10. Simpson A, Soderstrom L, Ahlstedt S, Murray CS, Woodcock A, Custovic A. IgE antibody quantification and the probability of wheeze in preschool children. *J Allergy Clin Immunol* 2005; **116**: 744–9.
11. Marinho S, Simpson A, Söderström L, Woodcock A, Ahlstedt S, Custovic A. Quantification of atopy and the probability of rhinitis in preschool children: a population-based birth cohort study. *Allergy* 2007; **62**: 1379–86.
12. Custovic A, Johnston SL, Pavord I, et al. EAACI position statement on asthma exacerbations and severe asthma. *Allergy* 2013; **68**: 1520–31.
13. Burney P, Malmberg E, Chinn S, Jarvis D, Luczynska C, Lai E. The distribution of total and specific serum IgE in the European Community Respiratory Health Survey. *J Allergy Clin Immunol* 1997; **99**: 314–22.
14. Jarvis D, Luczynska C, Chinn S, Burney P. The association of age, gender and smoking with total IgE and specific IgE. *Clin Exp Allergy* 1995; **25**: 1083–91.
15. Matsui EC, Sampson HA, Bahnson HT, et al. Allergen-specific IgE as a biomarker of exposure plus sensitization in inner-city adolescents with asthma. *Allergy* 2010; **65**: 1414–22.
16. Oryszczyn M-P, Bouzigon E, Maccario J, et al. Interrelationships of quantitative asthma-related phenotypes in the Epidemiological Study on the Genetics and Environment of Asthma, Bronchial Hyperresponsiveness, and Atopy. *J Allergy Clin Immunol* 2007; **119**: 57–63.
17. Kim EJ, Kwon JW, Lim YM, et al. Assessment of total/specific IgE levels against 7 inhalant allergens in children aged 3 to 6 years in Seoul, Korea. *Allergy, Asthma Immunol Res* 2013; **5**: 162–9.
18. Niemeijer NR, de Monchy JG. Age-dependency of sensitization to aero-allergens in asthmatics. *Allergy* 1992; **47**: 431–5.
19. Skassa-Brociek W, Manderscheid JC, Michel FB, Bousquet J. Skin test reactivity to histamine from infancy to old age. *J Allergy Clin Immunol* 1987; **80**: 711–6.
20. Bousquet J, Heinzerling L, Bachert C, et al. Practical guide to skin prick tests in allergy to aeroallergens. *Allergy* 2012; **67**: 18–24.
21. Custovic A, Simpson BM, Murray CS, et al. The national asthma campaign manchester asthma and allergy study. *Pediatr Allergy Immunol* 2002; **13**(Suppl. 15): 32–7.
22. Belgrave DC, Buchan I, Bishop C, Lowe L, Simpson A, Custovic A. Trajectories of lung function during childhood. *Am J Respir Crit Care Med* 2014; **189**: 1101–9.
23. Lodrup Carlsen KC, Roll S, Carlsen KH, et al. Does pet ownership in infancy lead to asthma or allergy at school age? Pooled analysis of individual participant data from 11 European birth cohorts. *PLoS One* 2012; **7**: e43214.
24. Belgrave DC, Granell R, Simpson A, et al. Developmental profiles of eczema, wheeze, and rhinitis: two population-based birth cohort studies. *PLoS Med* 2014; **11**: e1001748.
25. Pinart M, Benet M, Annesi-Maesano I, et al. Comorbidity of eczema, rhinitis, and asthma in IgE-sensitized and non-IgE-sensitized children in MeDALL: a population-based cohort study. *Lancet Respir Med* 2014; **2**: 131–40.
26. Custovic A, Sonntag HJ, Buchan IE, Belgrave D, Simpson A, Prosperi MC. Evolution pathways of IgE responses to grass and mite allergens throughout childhood. *J Allergy Clin Immunol* 2015; **136**: 1645–1652.
27. Prosperi MC, Belgrave D, Buchan I, Simpson A, Custovic A. Challenges in interpreting allergen microarrays in relation to clinical symptoms: a machine learning approach. *Pediatr Allergy Immunol* 2014; **25**: 71–9.
28. Simpson A, Lazic N, Belgrave DC, et al. Patterns of IgE responses to multiple allergen components and clinical symptoms at age 11 years. *J Allergy Clin Immunol* 2015; **136**: 1224–31.
29. Holt PG, Strickland D, Bosco A, et al. Distinguishing benign from pathologic T2 immunity in atopic children. *J Allergy Clin Immunol* 2015; pii:S0091-6749(15)01334-2. [Epub ahead of print].
30. Gough H, Grabenhenrich L, Reich A, et al. Allergic multimorbidity of asthma, rhinitis, and eczema over 20 years in the German birth cohort MAS. *Pediatr Allergy Immunol*. 2015; **26**: 431–437.

Supporting Information

Additional Supporting Information may be found in the online version of this article:

Figure E1. Consort figure demonstrating participant flow.

Table E1. Relationship between quantitative sensitization (skin test mean wheal diameter and the titre of sIgE) to mite, cat and dog allergens at different ages and the probability of current wheeze at the same age; LCL: Lower confidence level; UCL: Upper confidence level.

Table E2. Relationship between quantitative sensitization (skin test mean wheal diameter and the titre of sIgE) to mite, cat and dog allergens and current wheeze amongst males and females at different ages; LCL: Lower confidence level; UCL: Upper confidence level.

Table E3. Odds ratios for the relationship between quantitative atopic sensitisation and risk of wheeze and asthma in males and females of different ages.

Table E4. The relative odds ratios from discrete longitudinal analysis comparing the association between SPT MWD and sIgEs and probability of having co-morbid asthma, rhinitis and eczema at different ages.

Table E5. Odds ratios for the relationship between quantitative sensitisation (sum of mite, cat and dog allergens) and probability of having co-morbid asthma, eczema and rhinitis amongst boys and girls at different ages.

Table E6. The relative odds ratios from discrete longitudinal analysis comparing the association between SPT MWD (expressing SPT results as a ratio of MWD to allergens/MWD to histamine at each age) and current wheeze, current asthma and comorbid asthma, eczema and rhinitis at different ages.

Table E7. Odds ratios for the relationship between SPT MWD (expressing SPT results as a ratio of MWD to allergens/MWD to histamine at each age) current wheeze, current asthma and comorbid asthma, eczema and rhinitis in males and females of different ages.

Age, sex, and the association between skin test responses and IgE titres with asthma

ONLINE SUPPLEMENT

Hasan Raza Mohammad MRes¹, Danielle Belgrave PhD², Kamilla Kopec Harding PhD¹, Clare S
Murray MD¹, Angela Simpson MD PhD^{1*}, Adnan Custovic MD PhD^{2*}

¹Centre for Respiratory Medicine and Allergy, Institute of Inflammation and Repair, Manchester
Academic Health Science Centre, University of Manchester & University Hospital of South
Manchester, Manchester, United Kingdom

²Department of Paediatrics, Imperial College London, UK

*Joint senior authors

Corresponding author: Dr Hasan Mohammad

Figure E1. Consort figure demonstrating participant flow




Table E1. Relationship between quantitative sensitization (skin test mean wheal diameter and the titre of sIgE) to mite, cat and dog allergens at different ages and the probability of current wheeze at the same age; LCL: Lower confidence level; UCL; Upper confidence level

A- Mite allergen, B – Cat allergen and C – Dog allergen.

A

House dust mite				
<i>Skin Prick Test (Mean wheal diameter)</i>				
Age	ORs	LCL	UCL	P value
3 years	1.16	1.05	1.29	0.005
5 years	1.21	1.10	1.32	<0.001
8 years	1.59	1.44	1.75	<0.001
11 years	1.43	1.30	1.57	<0.001
<i>sIgE (Titre)</i>				
3 years	1.03	1.00	1.06	0.084
5 years	1.01	1.01	1.02	<0.001
8 years	1.02	1.01	1.02	<0.001

B

Cat				
<i>Skin Prick Test (Mean wheal diameter)</i>				
Age	ORs	LCL	UCL	P value
3 years	1.27	1.11	1.45	0.001
5 years	1.36	1.21	1.53	<0.001
8 years	1.63	1.44	1.84	<0.001
11 years	1.64	1.43	1.86	<0.001
<i>sIgE (Titre)</i>				
3 years	1.29	1.04	1.60	0.019
5 years	1.04	1.01	1.08	0.012
8 years	1.09	1.03	1.14	<0.001

C	Dog				
	<i>Skin Prick Test (Mean wheal diameter)</i>				
	Age	ORs	LCL	UCL	P value
	3 years	1.47	1.25	1.72	<0.001
	5 years	1.49	1.30	1.71	<0.001
	8 years	2.01	1.53	2.65	<0.001
	11 years	1.56	1.28	1.90	<0.001
	<i>sIgE (Titre)</i>				
	3 years	1.48	1.11	1.98	0.008
	5 years	1.01	0.99	1.03	0.176
	8 years	1.60	1.26	2.03	<0.001

Table E2. Relationship between quantitative sensitization (skin test mean wheal diameter and the titre of sIgE) to mite, cat and dog allergens and current wheeze amongst males and females at different ages; LCL: Lower confidence level; UCL; Upper confidence level

A- 3 years

B – 5 years

C – 8 years

D – 11 years.

Significant differenced highlighted in bold.

A: Age 3 years					
<i>Skin Prick Test (Mean wheal diameter)</i>					
Allergen	Gender	OR	LCL	UCL	P value
Mite	Male	1.16	1.03	1.31	0.017
	Female	1.13	0.90	1.41	0.289
Cat	Male	1.21	1.03	1.42	0.023
	Female	1.38	1.08	1.77	0.010
Dog	Male	1.41	1.17	1.69	<0.001
	Female	1.61	1.13	2.28	0.008
<i>sIgE (Titre)</i>					
Mite	Male	1.03	1.00	1.06	0.096
	Female	0.98	0.51	1.89	0.961
Cat	Male	1.20	0.99	1.45	0.062
	Female	2.71	1.08	6.80	0.034
Dog	Male	1.59	1.06	2.38	0.026
	Female	1.36	0.90	2.06	0.146

B: Age 5 years					
<i>Skin Prick Test (Mean wheal diameter)</i>					
Allergen	Gender	OR	LCL	UCL	P value
Mite	Male	1.15	1.03	1.27	0.011
	Female	1.31	1.10	1.56	0.003
Cat	Male	1.38	1.19	1.60	<0.001
	Female	1.31	1.09	1.58	0.004
Dog	Male	1.54	1.29	1.83	<0.001
	Female	1.34	1.06	1.68	0.013
<i>sIgE (Titre)</i>					
Mite	Male	1.01	1.00	1.01	0.011
	Female	1.02	1.00	1.03	0.012
Cat	Male	1.06	1.00	1.12	0.049
	Female	1.04	1.00	1.08	0.081
Dog	Male	1.43	1.02	1.99	0.038
	Female	1.01	0.99	1.02	0.464

C: Age 8 years					
<i>Skin Prick Test (Mean wheal diameter)</i>					
Allergen	Gender	OR	LCL	UCL	P value
Mite	Male	1.47	1.31	1.64	<0.001
	Female	1.87	1.56	2.24	<0.001
Cat	Male	1.51	1.30	1.75	<0.001
	Female	1.82	1.47	2.26	<0.001
Dog	Male	1.70	1.23	2.36	0.001
	Female	2.71	1.68	4.39	<0.001
<i>sIgE (Titre)</i>					
Mite	Male	1.01	1.01	1.02	<0.001
	Female	1.02	1.01	1.04	0.002
Cat	Male	1.09	1.01	1.18	0.026
	Female	1.08	1.01	1.16	0.019
Dog	Male	1.40	1.10	1.78	0.006
	Female	2.58	1.30	5.09	0.006

D: Age 11 years					
<i>Skin Prick Test (Mean wheal diameter)</i>					
Allergen	Gender	OR	LCL	UCL	P value
Mite	Male	1.38	1.17	1.48	<0.001
	Female	1.64	1.39	1.95	<0.001
Cat	Male	1.48	1.26	1.74	<0.001
	Female	1.91	1.51	2.43	<0.001
Dog	Male	1.41	1.10	1.81	0.007
	Female	1.81	1.28	2.56	0.001

Table E3. Odds ratios for the relationship between quantitative atopic sensitisation and risk of wheeze and asthma in males and females of different ages.

A) Current wheeze

B) Current asthma.

Bold: Significant changes in association.

A: Current wheeze					
SPT MWD (mite+cat+dog)					
Age	Gender	OR	Lower confidence level (LCL)	Upper confidence level (UCL)	P- value
3 years	Male	1.10	1.04	1.18	0.002
	Female	1.18	1.05	1.33	0.006
5 years	Male	1.15	1.08	1.22	<0.001
	Female	1.16	1.06	1.27	0.001
8 years	Male	1.33	1.23	1.44	<0.001
	Female	1.45	1.29	1.63	<0.001
11 years	Male	1.22	1.13	1.31	<0.001
	Female	1.41	1.25	1.58	<0.001
sIgE titre (mite+cat+dog)					
3 years	Male	1.05	1.00	1.09	0.032
	Female	1.35	0.90	2.01	0.144
5 years	Male	1.01	1.00	1.02	0.008
	Female	1.01	1.00	1.02	0.005
8 years	Male	1.01	1.01	1.02	<0.001
	Female	1.03	1.01	1.04	<0.001

Table E3 (continued)

B Current asthma					
SPT MWD (mite+cat+dog)					
Age	Gender	OR	Lower confidence level (LCL)	Upper confidence level (UCL)	P- value
3 years	Male	1.10	1.03	1.17	0.005
	Female	1.08	0.93	1.25	0.301
5 years	Male	1.15	1.09	1.22	<0.001
	Female	1.12	1.03	1.22	0.007
8 years	Male	1.29	1.20	1.39	<0.001
	Female	1.37	1.23	1.52	<0.001
11 years	Male	1.20	1.11	1.28	<0.001
	Female	1.38	1.23	1.55	<0.001
sIgE titre (mite+cat+dog)					
3 years	Male	1.03	1.00	1.06	0.024
	Female	1.13	0.58	2.20	0.718
5 years	Male	1.01	1.01	1.02	0.002
	Female	1.01	1.00	1.02	0.005
8 years	Male	1.01	1.01	1.01	<0.001
	Female	1.02	1.01	1.03	0.001

Table E4. The relative odds ratios from discrete longitudinal analysis comparing the association between SPT MWD and sIgEs and probability of having co-morbid asthma, rhinitis and eczema at different ages.

	Relative odds ratios	Lower confidence interval (LCL)	Upper confidence interval (UCL)	P – value
SPT MWD (mite+cat+dog)				
3 and 5	1.04	0.88	1.24	0.621
3 and 8	1.26	1.05	1.52	0.014
3 and 11	1.05	0.89	1.25	0.565
5 and 8	1.23	1.06	1.43	0.005
8 and 11	0.96	0.85	1.09	0.527
sIgE titre (mite+cat+dog)				
3 and 5	0.93	0.87	1.00	0.06
3 and 8	0.93	0.86	1.00	0.05
5 and 8	0.96	0.93	1.00	0.047

Table E5. Odds ratios for the relationship between quantitative sensitisation (sum of mite, cat and dog allergens) and probability of having co-morbid asthma, eczema and rhinitis amongst boys and girls at different ages.

SPT MWD (mite+cat+dog)					
Age	Gender	OR	Lower confidence level (LCL)	Upper confidence level (UCL)	P- value
3 years	Male	1.27	1.06	1.51	0.008
	Female	1.45	1.13	1.86	0.004
5 years	Male	1.29	1.17	1.43	0.000
	Female	1.70	1.28	2.27	0.000
8 years	Male	1.49	1.30	1.70	0.000
	Female	2.20	1.60	3.04	0.000
11 years	Male	1.35	1.19	1.53	0.000
	Female	1.44	1.17	1.79	0.001
sIgE titre (mite+cat+dog)					
3 years	Male	1.08	0.99	1.18	0.102
	Female	1.54	0.00	3.58 E 212	0.999
5 years	Male	1.02	1.01	1.03	0.001
	Female	1.79	0.77	4.14	0.174
8 years	Male	1.01	1.01	1.02	0.000
	Female	1.07	1.03	1.12	0.001

Table E6. The relative odds ratios from discrete longitudinal analysis comparing the association between SPT MWD (expressing SPT results as a ratio of MWD to allergens/MWD to histamine at each age) and current wheeze, current asthma and comorbid asthma, eczema and rhinitis at different ages.

Age group comparisons	Relative odds ratios	Lower confidence interval (LCL)	Upper confidence interval (UCL)	P – value
Current wheeze				
3 and 5	1.10	0.86	1.39	0.46
3 and 8	1.75	1.33	2.30	<0.001
3 and 11	1.50	1.05	2.14	0.03
5 and 8	1.67	1.32	2.11	<0.001
8 and 11	1.21	0.88	1.66	0.25
Current asthma				
3 and 5	1.08	0.84	1.38	0.55
3 and 8	1.60	1.22	2.10	0.001
3 and 11	1.65	1.23	2.22	0.001
5 and 8	1.54	1.23	1.94	<0.001
8 and 11	1.38	1.08	1.76	0.01
Co-morbid asthma, eczema and rhinitis				
3 and 5	1.14	0.67	1.92	0.64
3 and 8	1.95	1.10	3.45	0.02
3 and 11	1.36	0.77	2.43	0.29
5 and 8	1.83	1.15	2.90	0.01
8 and 11	1.05	0.67	1.63	0.84

Table E7. Odds ratios for the relationship between SPT MWD (expressing SPT results as a ratio of MWD to allergens/MWD to histamine at each age) current wheeze, current asthma and comorbid asthma, eczema and rhinitis in males and females of different ages.

Age	Gender	OR	Lower confidence level (LCL)	Upper confidence level (UCL)	P- value
Current wheeze					
3 years	Male	1.37	1.11	1.70	0.004
	Female	1.71	1.16	2.52	0.007
5 years	Male	1.57	1.31	1.89	<0.001
	Female	1.57	1.19	2.06	0.001
8 years	Male	2.35	1.84	3.01	<0.001
	Female	2.84	2.02	3.99	<0.001
11 years	Male	1.85	1.32	2.59	<0.001
	Female	4.03	1.95	8.33	<0.001
Current asthma					
3 years	Male	1.39	1.12	1.72	0.003
	Female	1.36	0.83	2.22	0.22
5 years	Male	1.56	1.30	1.88	<0.001
	Female	1.44	1.10	1.87	0.007
8 years	Male	2.20	1.73	2.80	<0.001
	Female	2.39	1.75	3.27	<0.001
11 years	Male	1.87	1.46	2.41	<0.001
	Female	4.19	2.61	6.72	<0.001
Co-morbid asthma, rhinitis, eczema					
3 years	Male	2.30	1.31	4.05	0.004
	Female	2.61	1.31	5.20	0.006

5 years	Male	2.20	1.60	3.01	<0.001
	Female	5.26	2.33	12.37	<0.001
8 years	Male	3.28	2.16	4.98	<0.001
	Female	11.17	4.20	19.73	<0.001
11 years	Male	2.75	1.76	4.29	<0.001
	Female	5.07	2.13	12.13	<0.001